Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 Jul 4;7(1):167. doi: 10.1186/s40425-019-0640-y.

2.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4. Review. Erratum in: J Immunother Cancer. 2019 Jul 4;7(1):167.

3.

Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.

Gubens MA, Sequist LV, Stevenson JP, Powell SF, Villaruz LC, Gadgeel SM, Langer CJ, Patnaik A, Borghaei H, Jalal SI, Fiore J, Saraf S, Raftopoulos H, Gandhi L.

Lung Cancer. 2019 Apr;130:59-66. doi: 10.1016/j.lungcan.2018.12.015. Epub 2018 Dec 17.

PMID:
30885353
4.

Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation.

Yang JC, Gadgeel SM, Sequist LV, Wu CL, Papadimitrakopoulou VA, Su WC, Fiore J, Saraf S, Raftopoulos H, Patnaik A.

J Thorac Oncol. 2019 Mar;14(3):553-559. doi: 10.1016/j.jtho.2018.11.028. Epub 2018 Dec 4.

PMID:
30529597
5.

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.

Gadgeel SM, Stevenson JP, Langer CJ, Gandhi L, Borghaei H, Patnaik A, Villaruz LC, Gubens M, Hauke R, Yang JC, Sequist LV, Bachman R, Saraf S, Raftopoulos H, Papadimitrakopoulou V.

Lung Cancer. 2018 Nov;125:273-281. doi: 10.1016/j.lungcan.2018.08.019. Epub 2018 Aug 25.

6.

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators.

N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.

7.

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators.

Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.

8.

The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC "Neutropenia, Infection and Myelosuppression" Study Group during the MASCC annual meeting held in Berlin on 27-29 June 2013.

Rapoport B, Klastersky J, Raftopoulos H, Freifeld A, Aoun M, Zinner SH, Rolston KV.

Support Care Cancer. 2016 Jul;24(7):2819-26. doi: 10.1007/s00520-016-3183-5. Epub 2016 Apr 20. No abstract available.

PMID:
27098065
9.

Chemotherapy-Induced Nausea and Vomiting.

Rapoport BL, Molasiotis A, Raftopoulos H, Roila F.

Biomed Res Int. 2015;2015:457326. doi: 10.1155/2015/457326. Epub 2015 Sep 6. No abstract available.

10.

Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.

Raftopoulos H, Laadem A, Hesketh PJ, Goldschmidt J, Gabrail N, Osborne C, Ali M, Sherman ML, Wang D, Glaspy JA, Puccio-Pick M, Zou J, Crawford J.

Support Care Cancer. 2016 Apr;24(4):1517-25. doi: 10.1007/s00520-015-2929-9. Epub 2015 Sep 14.

11.

Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.

Raftopoulos H, Boccia R, Cooper W, O'Boyle E, Gralla RJ.

Future Oncol. 2015 Sep;11(18):2541-51. doi: 10.2217/fon.15.185. Epub 2015 Aug 20.

PMID:
26289588
13.

Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication.

Rafael OC, Aziz M, Raftopoulos H, Vele OE, Xu W, Sugrue C.

Cancer Cytopathol. 2014 Jun;122(6):454-8. doi: 10.1002/cncy.21426. Epub 2014 Apr 10.

14.

The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia.

Klastersky J, Raftopoulos H, Rapoport B.

Support Care Cancer. 2013 Jun;21(6):1793-5. doi: 10.1007/s00520-013-1776-9. Epub 2013 Mar 24. No abstract available.

PMID:
23525960
15.

Activin receptor antagonists for cancer-related anemia and bone disease.

Fields SZ, Parshad S, Anne M, Raftopoulos H, Alexander MJ, Sherman ML, Laadem A, Sung V, Terpos E.

Expert Opin Investig Drugs. 2013 Jan;22(1):87-101. doi: 10.1517/13543784.2013.738666. Epub 2012 Nov 6. Review.

PMID:
23127248
16.

Oncologists as primary palliative care providers.

Hoffman MA, Raftopoulos H, Roy R.

J Clin Oncol. 2012 Aug 1;30(22):2801-2; author reply 2802. doi: 10.1200/JCO.2012.42.4655. Epub 2012 Jul 2. No abstract available.

PMID:
22753912
17.

Progress in the Control of Chemotherapy-Induced Emesis: New Agents and New Studies.

Gralla RJ, Raftopoulos H.

J Oncol Pract. 2009 May;5(3):130-133. doi: 10.1200/JOP.0938502.

18.

Carcinoma of the lung and metastatic disease of the central nervous system.

Austin JH, Mujoomdar A, Powell CA, Pearson GD, Raftopoulos H.

Am J Respir Crit Care Med. 2008 Nov 15;178(10):1090; author reply 1090. No abstract available.

PMID:
18987348
19.

Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials.

Bria E, Gralla RJ, Raftopoulos H, Cuppone F, Milella M, Sperduti I, Carlini P, Terzoli E, Cognetti F, Giannarelli D.

Lung Cancer. 2009 Jan;63(1):50-7. doi: 10.1016/j.lungcan.2008.05.002. Epub 2008 Jun 18.

PMID:
18565615
20.

Diagnosis and management of hyponatremia in cancer patients.

Raftopoulos H.

Support Care Cancer. 2007 Dec;15(12):1341-7. Epub 2007 Aug 14. Review.

PMID:
17701059
21.

A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer.

Ramanathan RK, Picus J, Raftopoulos H, Bernard S, Lockhart AC, Frenette G, Macdonald J, Melin S, Berg D, Brescia F, Hochster H, Cohn A.

Cancer Chemother Pharmacol. 2008 Mar;61(3):453-8. Epub 2007 May 22.

PMID:
17516069
22.

Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases.

Mujoomdar A, Austin JH, Malhotra R, Powell CA, Pearson GD, Shiau MC, Raftopoulos H.

Radiology. 2007 Mar;242(3):882-8. Epub 2007 Jan 17.

PMID:
17229875
23.

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.

Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Hustad CM, Horgan KJ, Skobieranda F; Aprepitant Moderately Emetogenic Chemotherapy Study Group.

Cancer. 2005 Oct 1;104(7):1548-55. Erratum in: Cancer. 2006 Apr 1;106(7):1641.

24.

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.

Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F.

J Clin Oncol. 2005 Apr 20;23(12):2822-30. Erratum in: J Clin Oncol. 2005 Aug 20;23(24):5851. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
15837996
25.

Supportive care in lung cancer.

Boyar M, Raftopoulos H.

Hematol Oncol Clin North Am. 2005 Apr;19(2):369-87, vii. Review.

PMID:
15833411
26.

Antiemetic studies on the NK1 receptor antagonist aprepitant.

Stoutenburg JP, Raftopoulos H.

J Natl Compr Canc Netw. 2004 Sep;2(5):491-7. Review.

PMID:
19780256
27.

A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor.

Haddad RI, Weinstein LJ, Wieczorek TJ, Bhattacharya N, Raftopoulos H, Oster MW, Zhang X, Latham VM Jr, Costello R, Faucher J, DeRosa C, Yule M, Miller LP, Loda M, Posner MR, Shapiro GI.

Clin Cancer Res. 2004 Jul 15;10(14):4680-7.

28.

A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.

Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC Jr, Tezcan H, Waples J, Ward J, Yee LK.

Cancer. 2004 Feb 15;100(4):859-68.

29.

Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy.

Liu-Jarin X, Stoopler MB, Raftopoulos H, Ginsburg M, Gorenstein L, Borczuk AC.

Mod Pathol. 2003 Nov;16(11):1102-8.

30.

Correction of phenotype in a thalassemia mouse model using a nonmyeloablative marrow transplantation regimen.

Bradley MB, Sattler RM, Raftopoulos H, Ward M, Grossman IR, Townes TM, Ryan TA, Bank A.

Biol Blood Marrow Transplant. 2002;8(8):453-61.

31.

Competitive repopulation of retrovirally transduced haemopoietic stem cells.

Qin S, Ward M, Raftopoulos H, Tang H, Bradley B, Hesdorffer C, Bank A.

Br J Haematol. 1999 Oct;107(1):162-8.

PMID:
10520037
32.

High-level transfer and long-term expression of the human beta-globin gene in a mouse transplant model.

Raftopoulos H, Ward M, Bank A.

Ann N Y Acad Sci. 1998 Jun 30;850:178-90.

PMID:
9668539
33.

Retroviral vectors aimed at the gene therapy of human beta-globin gene disorders.

Pawliuk R, Bachelot T, Raftopoulos H, Kalberer C, Humphries RK, Bank A, Leboulch P.

Ann N Y Acad Sci. 1998 Jun 30;850:151-62. Review.

PMID:
9668537
34.

Long-term transfer and expression of the human beta-globin gene in a mouse transplant model.

Raftopoulos H, Ward M, Leboulch P, Bank A.

Blood. 1997 Nov 1;90(9):3414-22.

PMID:
9345024
35.

Thrombocytopenia caused by isotretinoin.

Hesdorffer CS, Weltman MD, Raftopoulos H, Mendelow B, Bezwoda WR.

S Afr Med J. 1986 Nov 22;70(11):705-6. No abstract available.

PMID:
3466373

Supplemental Content

Loading ...
Support Center